Oculis (NASDAQ:OCS) Trading Down 4.6% – What’s Next?

Oculis Holding AG (NASDAQ:OCS)’s share price fell 4.6% during mid-day trading on Friday . The stock traded as low as $11.15 and last traded at $10.9450. 10,477 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 444,602 shares. The stock had previously closed at $11.47.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on OCS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research report on Friday, July 17th. Stifel Nicolaus lowered their price target on shares of Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, June 1st. JPMorgan Chase & Co. cut their price objective on Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Robert W. Baird dropped their target price on Oculis from $49.00 to $38.00 and set an “outperform” rating on the stock in a research report on Monday, June 1st. Finally, Needham & Company LLC lowered their price target on Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Oculis Price Performance

The stock has a 50 day moving average of $12.45 and a two-hundred day moving average of $19.68. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.35 and a current ratio of 8.35. The firm has a market capitalization of $632.97 million, a P/E ratio of -6.28 and a beta of 0.52.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.20) EPS for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. The company had revenue of $0.38 million for the quarter. Sell-side analysts predict that Oculis Holding AG will post -2.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

Institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its position in shares of Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Oculis during the second quarter worth approximately $393,000. Bank of America Corp DE boosted its position in shares of Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after acquiring an additional 878 shares during the period. Woodline Partners LP grew its stake in shares of Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after acquiring an additional 33,265 shares during the last quarter. Finally, Simplify Asset Management Inc. bought a new position in Oculis during the fourth quarter worth $1,972,000. 22.30% of the stock is currently owned by institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.